CD276-CSANs

CD276-CSANs are chemically self-assembled nanorings (CSANs) designed to target and inhibit CD276 (B7-H3), an immune checkpoint molecule frequently overexpressed in various malignancies, including medulloblastoma. Developed through a collaboration between the Houston Methodist Research Institute and the University of Minnesota, these nanorings are constructed using a protein engineering platform where fusion proteins containing dihydrofolate reductase (DHFR) domains are induced to self-assemble into multivalent rings in the presence of a chemical dimerizer. CD276-CSANs function by blocking the interaction between CD276 on tumor cells and its ligands on immune cells, thereby reversing CD276-mediated suppression of CD8+ T cells. Preclinical studies in Sonic Hedgehog (SHH) medulloblastoma models have demonstrated that systemic administration of CD276-CSANs can enhance anti-tumor immune responses and improve survival, particularly in male subjects where the Yap1-B7-H3 signaling axis is a prominent driver of immune evasion.

Other names

B7-H3-CSANsB-7-H3-CSANsB 7-H3-CSANsCD276-targeting chemically self-assembled nanoringsCD-276-targeting chemically self-assembled nanoringsCD 276-targeting chemically self-assembled nanorings